Mr. Bill Zhang reports

DRI HEALTHCARE TRUST ANNOUNCES CLOSING OF PREFERRED SECURITIES REFINANCING

DRI Healthcare Trust has successfully completed the closing of the previously announced private placement offering of convertible unsecured subordinated debentures in the aggregate principal amount of $108,723,000.

The principal sum of the debentures bear interest at the rate of 5.75 per cent per annum, payable semi-annually in arrears, and mature on Feb. 28, 2031. The debentures will be convertible at the option of the holder into units of DRI Healthcare at a conversion price of $21.99 per unit, representing a premium of 30 per cent to the three-day volume-weighted average price (VWAP) of the closing price of the units on Feb. 27, 2026.

The purchase price for the debentures was exclusively satisfied through the exchange of $79,698,000 (U.S.) aggregate principal amount of the outstanding 7.50 per cent Series C preferred securities, with such preferred securities exchanged at a currency adjusted principal amount equal to the principal amount of debentures issued. As of the date hereof, an aggregate principal amount of $35.58-million of the preferred securities remain issued and outstanding.

About DRI Healthcare Trust

DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since its founding in 1989, it has deployed more than $3.0-billion, acquiring more than 75 royalties on 50-plus drugs, including Ekterly, Eylea, Keytruda, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga.

We seek Safe Harbor.